{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:05:10Z","timestamp":1774983910692,"version":"3.50.1"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ctrv.2022.102435","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T01:55:05Z","timestamp":1657245305000},"page":"102435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Impact of molecular profiling on the management of patients with myelofibrosis"],"prefix":"10.1016","volume":"109","author":[{"given":"Irene","family":"Pastor-Gal\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2022.102435_b0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2022.102435_b0010","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","article-title":"Myeloproliferative neoplasms: from origins to outcomes","volume":"130","author":"Nangalia","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102435_b0015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102435_b0020","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.ctrv.2022.102435_b0025","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2017009530","article-title":"Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1\/2 inhibitor therapy","volume":"1","author":"Spiegel","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102435_b0030","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102435_b0035","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0040","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/joim.13019","article-title":"Incidence of myeloproliferative neoplasms \u2013 trends by subgroup and age in a population-based study in Sweden","volume":"287","author":"Hultcrantz","year":"2020","journal-title":"J Int Med"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0045","first-page":"152","article-title":"Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis","volume":"155","author":"Pastor-Galan","year":"2020","journal-title":"Med Clin (Barc)"},{"issue":"24","key":"10.1016\/j.ctrv.2022.102435_b0050","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"59","key":"10.1016\/j.ctrv.2022.102435_b0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"02","author":"Masarova","year":"2017","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102435_b0060","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.bbmt.2015.09.005","article-title":"Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all age groups","volume":"21","author":"Deeg","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102435_b0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41375-020-0815-z","article-title":"Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation","volume":"35","author":"Hernandez-Boluda","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102435_b0070","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Luque Paz","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102435_b0075","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0080","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2016.351","article-title":"Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102435_b0085","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ctrv.2022.102435_b0090","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"issue":"52","key":"10.1016\/j.ctrv.2022.102435_b0095","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102435_b0100","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102435_b0105","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102435_b0110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/leu.2014.270","article-title":"Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution","volume":"29","author":"Cabagnols","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102435_b0115","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102435_b0120","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102435_b0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102435_b0130","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102435_b0135","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.ctrv.2022.102435_b0140","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102435_b0145","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8081.1","article-title":"Recent advances in understanding myelofibrosis and essential thrombocythemia","volume":"5","author":"Vainchenker","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.ctrv.2022.102435_b0150","article-title":"Targeted molecular characterization shows differences between primary and secondary myelofibrosis","author":"Courtier","year":"2019","journal-title":"Genes Chromosom Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102435_b0155","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2021006350","article-title":"ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102435_b0160","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102435_b0165","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/leu.2011.161","article-title":"Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.ctrv.2022.102435_b0170","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102435_b0175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clml.2020.01.008","article-title":"The myelodepletive phenotype in myelofibrosis: clinical relevance and therapeutic implication","volume":"20","author":"Marcellino","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102435_b0180","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2022.102435_b0185","doi-asserted-by":"crossref","unstructured":"Coltro GMF, Loscocco G, Mannarelli C, Rotunno G, Maccari C, et al. A myelodepletive phenotype is associated with distinctive molecular features and adverse outcomes in patients with myelofibrosis. Blood 2021;138 (Supplement 1):1498.","DOI":"10.1182\/blood-2021-146600"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0190","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/L18-0245","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms","volume":"169","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0195","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102435_b0200","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/leu.2014.343","article-title":"CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis","volume":"29","author":"Finazzi","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102435_b0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ctrv.2022.102435_b0210","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102435_b0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","article-title":"Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis","volume":"10","author":"Guglielmelli","year":"2020","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1016\/j.ctrv.2022.102435_b0220","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102435_b0225","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102435_b0230","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102435_b0235","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.14762","article-title":"Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia","volume":"178","author":"Alvarez-Larran","year":"2017","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.ctrv.2022.102435_b0240","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1182\/bloodadvances.2020002271","article-title":"Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation","volume":"4","author":"Luque Paz","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102435_b0245","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102435_b0250","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102435_b0255","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102435_b0260","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-019-0175-y","article-title":"Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model","volume":"9","author":"Vallapureddy","year":"2019","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.ctrv.2022.102435_b0265","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102435_b0270","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kroger","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102435_b0275","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"16","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102435_b0280","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0285","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102435_b0290","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2016.149765","article-title":"An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis","volume":"102","author":"Rozovski","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0295","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102435_b0300","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102435_b0305","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102435_b0310","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102435_b0315","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.6004\/jnccn.2020.7557","article-title":"A practical guide for using myelofibrosis prognostic models in the clinic","volume":"18","author":"How","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"20","key":"10.1016\/j.ctrv.2022.102435_b0320","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102435_b0325","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0330","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br J Haematol."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102435_b0335","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01266.x","article-title":"Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level","volume":"83","author":"Huang","year":"2009","journal-title":"Eur J Haematol."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0340","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.12846","article-title":"Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis","volume":"98","author":"Hernandez-Boluda","year":"2017","journal-title":"Eur J Haematol."},{"issue":"12","key":"10.1016\/j.ctrv.2022.102435_b0345","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-018-0158-4","article-title":"Genetic predictors of response to specific drugs in primary myelofibrosis","volume":"8","author":"Penna","year":"2018","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102435_b0350","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","article-title":"Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups","volume":"162","author":"Ianotto","year":"2013","journal-title":"Br J Haematol."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102435_b0355","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3324\/haematol.2017.181297","article-title":"Benefits and pitfalls of pegylated interferon-alpha2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study","volume":"103","author":"Ianotto","year":"2018","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.ctrv.2022.102435_b0360","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30679","article-title":"The effect of initial molecular profile on response to recombinant interferon-alpha (rIFNalpha) treatment in early myelofibrosis","volume":"123","author":"Silver","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102435_b0365","doi-asserted-by":"crossref","first-page":"e956","DOI":"10.1016\/j.clml.2020.07.006","article-title":"Retrospective analysis of the clinical use and benefit of lenalidomide and thalidomide in myelofibrosis","volume":"20","author":"Castillo-Tokumori","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.ctrv.2022.102435_b0370","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.ctrv.2022.102435_b0375","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102435_b0380","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2020.262691","article-title":"Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications","volume":"106","author":"Ross","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102435_b0385","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med."},{"issue":"25","key":"10.1016\/j.ctrv.2022.102435_b0390","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102435_b0395","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.ctrv.2022.102435_b0400","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102435_b0405","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"7414","key":"10.1016\/j.ctrv.2022.102435_b0410","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0415","doi-asserted-by":"crossref","first-page":"e52904","DOI":"10.15252\/embr.202152904","article-title":"Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody","volume":"23","author":"Tvorogov","year":"2022","journal-title":"EMBO Rep"},{"key":"10.1016\/j.ctrv.2022.102435_b0420","doi-asserted-by":"crossref","first-page":"637420","DOI":"10.3389\/fonc.2021.637420","article-title":"Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients With CALR-mutant chronic myeloproliferative neoplasms","volume":"11","author":"Handlos Grauslund","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102435_b0425","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.ctrv.2022.102435_b0430","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102435_b0435","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102435_b0440","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102435_b0445","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kroger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102435_b0450","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbmt.2020.07.022","article-title":"Predicting survival after allogeneic hematopoietic cell transplantation in myelofibrosis: performance of the myelofibrosis transplant scoring system (MTSS) and development of a new prognostic model","volume":"26","author":"Hernandez-Boluda","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2022.102435_b0455","doi-asserted-by":"crossref","unstructured":"Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, et al. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen. Blood Adv 2019;3(1):83-95.","DOI":"10.1182\/bloodadvances.2018026658"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102435_b0460","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","article-title":"Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis","volume":"25","author":"Tamari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.ctrv.2022.102435_b0465","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102435_b0470","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party","volume":"35","author":"McLornan","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102435_b0475","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3324\/haematol.2012.076901","article-title":"JAK2 p. V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse","volume":"98","author":"Lange","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102435_b0480","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2017.157","article-title":"Impact of molecular residual disease post allografting in myelofibrosis patients","volume":"52","author":"Wolschke","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102435_b0485","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","article-title":"JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation","volume":"113","author":"Kroger","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102435_b0490","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41409-022-01566-0","article-title":"Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis","volume":"57","author":"Mannina","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102435_b0495","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102435_b0500","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102435_b0505","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41375-018-0347-y","article-title":"ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis","volume":"33","author":"Guo","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102435_b0510","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102435_b0515","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1002\/ajh.25668","article-title":"Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms","volume":"95","author":"Guglielmelli","year":"2020","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.ctrv.2022.102435_b0520","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2020010402","article-title":"Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms","volume":"138","author":"Marcault","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102435_b0525","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102435_b0530","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2016-04-711150","article-title":"LNK mutations in familial myeloproliferative neoplasms","volume":"128","author":"Rumi","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102435_b0535","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102435_b0540","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbmt.2017.09.016","article-title":"Hematopoietic cell transplantation for myelofibrosis: the dynamic international prognostic scoring system plus risk predicts post-transplant outcomes","volume":"24","author":"Samuelson Bannow","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102435_b0545","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.bbmt.2020.08.024","article-title":"Australasian trends in allogeneic stem cell transplantation for myelofibrosis in the molecular era: a retrospective analysis from the australasian bone marrow transplant recipient registry","volume":"26","author":"Lwin","year":"2020","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:08Z","timestamp":1759656428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":109,"alternative-id":["S0305737222001049"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102435","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of molecular profiling on the management of patients with myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102435"}}